SHORT REPORT

Cerebral microbleeds and the risk of intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: systematic review and meta-analysis

Andreas Charidimou,1 Puneet Kakar,2 Zoe Fox,3,4 David J Werring1

ABSTRACT

Background Intracerebral haemorrhage (ICH) remains the most devastating yet unpredictable complication of intravenous thrombolysis for acute ischaemic stroke. We performed a systematic review and meta-analysis, to assess whether the presence of cerebral microbleeds (CMBs) on prethrombolysis MRI scans is associated with an increased risk of ICH.

Methods We searched PubMed for studies assessing ICH risk in patients with acute ischaemic stroke treated with thrombolysis, in relation to the presence of pretreatment CMBs.

Results We identified five studies including 790 patients and pooled data in a meta-analysis. The CMB (+) versus CMB (−) groups were not significantly different in age, gender or stroke severity. The overall prevalence of CMBs was 135/790 (17.1%). Amongst patients with CMBs, 10/135 (7.4%) experienced a symptomatic ICH after thrombolysis, compared to 29/655 (4.4%) patients without CMBs. The pooled relative risk of ICH was 1.90 (95% CI 0.92 to 3.93; p=0.082).

Conclusions The available evidence does not demonstrate a statistically significant increased risk of symptomatic ICH after thrombolysis for ischaemic stroke in patients with CMBs. However, in view of the methodological limitations of the studies included, the clinical relevance of any potential hazard associated with CMBs remains uncertain. Further studies are warranted to evaluate whether the risk of ICH might outweigh the benefit of thrombolysis, especially in patients with multiple lobar CMBs suggestive of cerebral amyloid angiopathy.

INTRODUCTION

Intravenous thrombolysis is the only effective licensed treatment for acute ischaemic stroke. However, the improved outcomes overall come at the cost of a small increase in risk of intracerebral haemorrhage (ICH), the most devastating yet unpredictable complication.1 Symptomatic ICH occurs in about 2.4–10% of cases within 24–36 h of thrombolysis (depending on the definition used), and may be disabling.1,2 Identifying patients at higher risk for ICH following thrombolysis is thus an urgent clinical priority: a reliable and safe way to do this could increase the overall safety profile of this widely used treatment. Markers of increased risk include increasing age, early ischaemic CT changes, high blood pressure, hyperglycaemia, clinical stroke severity as assessed by the National Institute of Health Stroke Scale score on admission, large baseline diffusion lesion volume and cerebral white matter changes (leukoaraiosis), but there is currently no reliable way to predict severe ICH.1 Cerebral microbleeds (CMBs)—small perivascular haemorrhages seen as well-demarcated, hypointense, rounded lesions on MRI sequences sensitive to magnetic susceptibility—are a marker of haemorrhage-prone microangiopathies (mainly hypertensive arteriopathy or cerebral amyloid angiopathy (CAA)). Because CMBs are a rather specific marker for previous bleeding from pathologically fragile cerebral small vessels,3 they might help to identify a subpopulation of patients at high risk of clinically significant ICH.4 Previous studies have given conflicting results regarding the possible risk of ICH after thrombolysis in individuals with CMBs.5,6 We therefore performed a systematic review and meta-analysis to assess the evidence whether the presence of CMBs on pretreatment MRI scans is associated with an increased risk of ICH.

METHODS

Search strategy and selection criteria

We searched PubMed between 1 January 1995 and 1 February 2012 using the following search terms: ‘microbleed(s)’, or ‘micro(-)h(a)emorrhage(s)’, or ‘gradient-echo’ in association with ‘thrombol*’ or ‘tPA’, or ‘tissue plasminogen activator’. Reference lists from all included articles and the authors’ own files were also searched for relevant publications. Papers not published in English and case reports were excluded. Two authors (AC and PK) identified potentially relevant studies, resolving any uncertainties with a third author (DJW).

Eligibility criteria

Studies were eligible for inclusion if they had assessed ICH risk in patients with acute ischaemic stroke treated with thrombolysis, and quantified this risk in relation to the presence of CMBs on pretreatment MRI scans.

Data extraction

Two authors (AC and PK) went through all articles selected as potentially relevant and extracted data independently. We extracted information on type of study; number and nature of participants (including mean age and sex); MRI parameters, duration of follow-up, number of participants with at least one CMB and number of participants with the outcome event (symptomatic ICH defined according to standard criteria). Consensus was reached by discussion.
Cerebrovascular disease

Studies were critically appraised against a checklist of key quality indicators with reference to the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) statement and the ideal characteristics for a study of CMBs (see online supplementary table S1) (Clearly defined CMB criteria, clear definition of the study population, standardised MRI parameters, clearly defined ICH criteria, awareness of ≥2 CMB mimics, standardised rating scale or trained observer with reported inter-rater/intra-rater agreement, data on CMB distribution and adjustment for other ICH risk factors).

Meta-analysis

We used a fixed effects model to calculate the pooled relative risk (RR) of symptomatic ICH in patients with versus without CMBs, where weights were calculated using the inverse variance method. We assessed heterogeneity using I-squared and x-squared statistics and through visual inspection of the forest plot. We explored publication bias with the funnel plot. Meta-analyses were performed using Stata 11.2 (StataCorp LE, Texas, USA). We prepared this report with reference to MOOSE (meta-analyses of observational studies) guidelines.6

RESULTS

We identified 62 articles in our initial search of PubMed; five studies including a total of 790 patients (135 with CMBs) met our inclusion criteria, and were pooled in a meta-analysis.5 6-11 One study was excluded12 because of overlap with a previously published cohort.9 A summary of the characteristics of included studies is provided in table 1 and online supplementary tables S2 and S3. There was no evidence of publication bias in the funnel plot (see online supplementary figure S1). The CMB (+) versus CMB (−) groups were not significantly different in age, gender or stroke severity, except that in one study higher age was associated with CMBs.9 The overall prevalence of CMBs on pretreatment MRI scans was 17.1%. Amongst patients with CMBs, 10/135 (7.4%) experienced a symptomatic ICH after thrombolysis, compared to 29/655 (4.4%) patients without CMBs; the pooled RR of ICH was 1.90 (95% CI 0.92 to 3.93; p=0.082) (figure 1). The results were consistent from study to study (p=0.800).

DISCUSSION

Our systematic review and meta-analysis in nearly 800 patients with acute ischaemic stroke shows that the presence of CMBs on a pretreatment MRI scan is not associated with a statistically significant increased risk of symptomatic ICH following thrombolysis. However, there was a trend for a higher ICH risk in those patients with CMBs (pooled RR 1.90; 95% CI 0.92 to 3.93; p=0.082).

With the introduction of T2*-weighted gradient-recalled echo (T2*-GRE) and susceptibility-weighted imaging, CMBs are increasingly detected in patients with acute ischaemic stroke.4 Evidence suggests that CMBs are a prognostic marker for future ICH risk after stroke.13 14 However, only five studies have reported on the risk of ICH following thrombolysis for acute ischaemic stroke in patients screened for CMBs.5 6 9–11 Recent studies indicate that the rate of symptomatic thrombolysis-related ICH is increased in the presence of moderate-to-severe leukoaraiosis, implying that cerebral small vessel is a risk factor for ICH.15 16 However, leukoaraiosis lacks pathological specificity, by contrast with CMBs, which appear to specifically reflect small areas of haemorrhage from vessels affected by bleeding-prone arteriopathies (mainly hypertensive arteriopathy or CAA).8 Several methodological aspects of the included studies deserve consideration. Importantly, most had a small sample size; only the multicentre BRASIL (bleeding risk analysis in stroke imaging before thrombolysis) study (n=570) had more than 100 patients, and hence dominated our meta-analysis.5 Furthermore, all studies are subject to selection bias since not all acute stroke patients undergo T2*-GRE, and such patients were excluded.

Imaging parameters varied between studies, which could affect the prevalence of CMBs.4 17 In some centres in the BRASIL study6 a small proportion of stroke patients had CMBs, and only six patients had five or more CMBs, suggesting that some MRI protocols were not optimal to detect CMBs, which are typically found in about 20–30% of ischaemic stroke patients.9 Moreover, the studies did not use standardised rating scales for CMBs, and did not report on ICH risk in relation to CMB number and anatomical location.

Although the outcome definitions for ICH were not standardised among the studies included, all included ICH associated with clinical deterioration and thus likely to be clinically relevant. A range of different thrombolysis protocols were used (table 1 and online supplementary table S5); for example Kim et al8 included both intravenous and intra-arterial thrombolysis, but found no statistically significant difference between the groups in haemorrhagic complications.9 The study by Derex et al8 included two drug doses but found no significant influence of dose on the risk of ICH.

Some studies did not provide full details of some baseline characteristics likely to be important for thrombolysis-related ICH, for example, hyperglycaemia, hypertension, prior use of antiplatelet and anticoagulant medications or recurrent stroke.

CMBs might increase the risk of thrombolysis-related ICH either as the direct source of the ICH, or as a general marker of small vessel fragility. About 20% of patients with acute ischaemic stroke develop new CMBs in the first few days,18 suggesting an active, diffuse microangiopathy, which with the administration of thrombolysis could cause symptomatic ICH. Since most new CMBs in this study18 developed in patients with baseline CMBs, prethrombolysis CMBs may be a marker for patients at most risk of symptomatic ICH. However, the free circulating plasma half-life of alteplase is very short (between 4–6 min), and that the exact mechanisms of ICH post-thrombolysis remain uncertain.

Deep CMBs in the basal ganglia and brainstem are most likely related to hypertensive arteriopathy, while multiple strictly lobar CMBs are likely to reflect CAA.4 CAA may be a particular risk factor for post-thrombolysis ICHs, which are often lobar, multiple and occur remote from the infarct in around 20% of patients.19 Pathological studies also support a role of pre-existing CAA: one study reported that 70% of patients with thrombolysis-related ICH had autopsy-proven CAA compared to 22% of unselected ICH patients of similar age.20 Finally, an increased risk of ICH was associated with intravenous thrombolysis in CAA transgenic mice.21 Strictly lobar CMBs form an important part of recent diagnostic criteria for CAA,22 so may be of particular prognostic value for ICH, but this has not been addressed by previous studies.

CONCLUSIONS

Our analysis suggests a trend of increased risk of symptomatic ICH after thrombolysis for ischaemic stroke if CMBs are present on pretreatment MRI. Although the risk was not statistically significant at the 0.05 level, the data do not rule out a possible clinically important increased hazard for thrombolysis in
<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Patient number (% men)</th>
<th>Mean age (years)</th>
<th>Initial stroke severity (NIHSS)</th>
<th>Field strength (Tesla)</th>
<th>Echo time (ms)</th>
<th>Section thickness (mm)</th>
<th>CMBs prevalence (95% CI)</th>
<th>Differences CMBs (+) versus CMBs (−) groups</th>
<th>Thrombolysis (see online supplementary table S3)</th>
<th>FU time (days)</th>
<th>Symptomatic ICH definition</th>
<th>Other risk factors for thrombolysis-related ICH accounted for</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fiehler</td>
<td>Prospective, multicentre (13)</td>
<td>570 (–)</td>
<td>69 (59–77)*</td>
<td>13 (IQR:8–17)</td>
<td>14–49</td>
<td>5–7</td>
<td>15.1% (9.1 to 19.7%)</td>
<td>No differences in: sex and NIHSS score. Median age (IQR): 72 (65–78) versus 69 (59–77); (p=0.001)</td>
<td>IV tPA within 6 h</td>
<td>10</td>
<td>ICH with worsening of ≥4 points on NIHSS</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Kim</td>
<td>Retrospective, single centre</td>
<td>65 (57)</td>
<td>67</td>
<td>–</td>
<td>–</td>
<td>30</td>
<td>5</td>
<td>15.7% (8.1 to 26.4%)</td>
<td>Hypertension and age associated with CMBs (p&lt;0.05)</td>
<td>IV tPA within 3 h (n=12); IA UK within 6 h (n=53)</td>
<td>1–3</td>
<td>Symptomatic haemorrhage: any neurological deterioration within the first 48 h that could be attributed to the presence haemorrhage on follow-up MRI</td>
<td>Age, hypertension, diabetes, atrial fibrillation, stroke history, smoking, NIHSS score</td>
</tr>
<tr>
<td>Kakuda</td>
<td>Prospective, multicentre (3)</td>
<td>70 (44.3)</td>
<td>70.5</td>
<td>11±9.2/12±9.8 CMB (+)/(-) (mean/SD)</td>
<td>1.5</td>
<td>14–47</td>
<td>5</td>
<td>38.5% (26.7 to 51.4%)</td>
<td>No differences in age, time to treatment, blood pressure, NIHSS, hypertension. Diabetes, dyslipidaemia, smoking</td>
<td>IV tPA within 6 h</td>
<td>30</td>
<td>ICH with worsening of ≥2 points on NIHSS</td>
<td>–</td>
</tr>
<tr>
<td>Derex</td>
<td>Retrospective, single centre</td>
<td>44 (–)</td>
<td>63.2+/–14.1</td>
<td>14±5.8 (mean ± SD)</td>
<td>1.5</td>
<td>26</td>
<td>5</td>
<td>18.2% (8.2 to 32.7%)</td>
<td>–</td>
<td>IV tPA at two different doses within 7 h</td>
<td>7</td>
<td>ICH with worsening of ≥4 points on NIHSS or ≥1 point on NIHSS consciousness level</td>
<td>Delay to treatment; tPA dose</td>
</tr>
<tr>
<td>Kidwell</td>
<td>Retrospective, single centre</td>
<td>41 (–)</td>
<td>–</td>
<td>–</td>
<td>1.5</td>
<td>15</td>
<td>7</td>
<td>12.2% (4.1 to 26.2%)</td>
<td>No differences in age, hypertension, diabetes, hypercholesterolaemia, smoking, and severity of pretreatment neurological deficit.</td>
<td>IV/IA tPA within 3 h; IA UK or tPA mechanical clot disruption during IA thrombolysis</td>
<td>7</td>
<td>ICH with worsening of ≥4 points on NIHSS or ≥1 point on NIHSS consciousness level</td>
<td>Thrombolysis regimen</td>
</tr>
</tbody>
</table>

CMB, cerebral microbleeds; FU, follow-up; GRE, gradient-recalled echo; IA: intra-arterial; ICH, intracerebral haemorrhage; IQR, interquartile range; IV, intravenous; NIHSS, National Institute of Health Stroke Scale; SD, standard deviation; tPA, tissue plasminogen activator. *Median age (interquartile range)
individuals with CMBs, particularly in view of the significant methodological limitations of included reports. Our data thus reinforce the need for further large multicentre studies (for suggested ideal study characteristics see online supplementary table S1) to evaluate whether the risk of ICH outweighs the benefit of thrombolysis in patients with CMBs, particularly those with multiple lobar CMBs suggestive of CAA.2,3

Figure 1 Meta-analysis of the association between intracerebral haemorrhage (ICH) risk in patients with acute ischaemic stroke treated with thrombolysis, in relation to the presence of cerebral microbleeds (CMBs) on pretreatment MRI scans. This figure is only reproduced in colour in the online version.

Table 1

<table>
<thead>
<tr>
<th>Study</th>
<th>CMB (-) n/N</th>
<th>CMB (+) n/N</th>
<th>Relative risk (95% CI)</th>
<th>Weight(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fiehler 2007</td>
<td>13/484</td>
<td>5/86</td>
<td>2.16 (0.79, 5.92)</td>
<td>51.95</td>
</tr>
<tr>
<td>Kim      2006</td>
<td>2/40</td>
<td>3/25</td>
<td>2.40 (0.43, 13.38)</td>
<td>17.80</td>
</tr>
<tr>
<td>Kakuda 2005</td>
<td>7/59</td>
<td>0/11</td>
<td>0.33 (0.02, 5.45)</td>
<td>6.73</td>
</tr>
<tr>
<td>Derex 2004</td>
<td>2/36</td>
<td>1/8</td>
<td>2.25 (0.23, 21.89)</td>
<td>10.15</td>
</tr>
<tr>
<td>Kidwell 2002</td>
<td>4/36</td>
<td>1/5</td>
<td>1.80 (0.25, 13.06)</td>
<td>13.38</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>28/555</strong></td>
<td><strong>10/135</strong></td>
<td><strong>1.90 (0.92, 3.93)</strong></td>
<td><strong>100.00</strong></td>
</tr>
</tbody>
</table>

Test for heterogeneity: $\chi^2=1.65, df=4, p=0.00, I^2=0.00%$
Test for overall effect: $z=1.74, p=0.082$

REFERENCES

Cerebral microbleeds and the risk of intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: systematic review and meta-analysis

Andreas Charidimou, Puneet Kakar, Zoe Fox and David J Werring

*J Neurol Neurosurg Psychiatry* 2013 84: 277-280 originally published online September 28, 2012
doi: 10.1136/jnnp-2012-303379

Updated information and services can be found at:
http://jnnp.bmj.com/content/84/3/277

These include:

**Supplementary Material**
Supplementary material can be found at:
http://jnnp.bmj.com/content/suppl/2012/09/27/jnnp-2012-303379.DC1

**References**
This article cites 23 articles, 11 of which you can access for free at:
http://jnnp.bmj.com/content/84/3/277#ref-list-1

**Open Access**
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Open access (270)
- Stroke (1449)
- Radiology (1747)
- Radiology (diagnostics) (1309)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/